Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Monthly Archives: June 2022

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH Footprint Extends to Europe with License Granted to Valcon Medical

Posted on June 2, 2022 by MissionIR

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has awarded licensing of its proprietary DehydraTECH(TM) offering for development in the European and United Kingdom markets. The company awarded the nonexclusive licenses to Valcon Medical A/S, a European contract … Continue reading →

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Host Webinar Delving into Psychedelics Landscape, Current and Emerging Therapeutics

Posted on June 2, 2022 by MissionIR

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that it will host a virtual Key Opinion Leader webinar from 11:00 a.m. to 12:00 p.m. ET on Thursday, June 9, 2022. The … Continue reading →

Posted in Cybin Inc. CYBN | Leave a comment

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces $5M Registered Direct and Private Placement Offerings

Posted on June 2, 2022 by MissionIR

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the research, development, manufacturing and commercialization of rare cannabinoids. The company today announced its entry into securities purchase agreements with a single health care-focused institutional investor for the issuance and sale of … Continue reading →

Posted in InMed Pharmaceuticals Inc. INM | Leave a comment

EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF) Poised to Execute Rapid Growth Strategy; Announces Acquisition of 50% Stake in Project Radius in Ontario

Posted on June 2, 2022 by MissionIR

EverGen appears poised to deliver on its rapid growth strategy and solidify its market position within the RNG space Company announced acquisition of 50% stake of Ontario’s Project Radius, following recently announced plans to acquire a 67% interest in Alberta-based … Continue reading →

Posted in EverGen Infrastructure Corp. EVGIF | Leave a comment

MissionIRNewsBreaks – Pressure BioSciences Inc. (PBIO) CEO Discusses UST(TM) Platform, Early Access Program on Stock Day Podcast

Posted on June 1, 2022 by MissionIR

Pressure BioSciences (OTCQB: PBIO) (“PBI”) is a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables and specialty testing services for the worldwide life sciences markets and other industries. The company was featured in a recent … Continue reading →

Posted in Pressure BioSciences Inc. PBIO | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on 2022 Annual Meeting Voting

Posted on June 1, 2022 by MissionIR

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has released a report on its recent 2022 Annual Meeting and the items that were voted on. The meeting was held on May 31, 2022, at 1 p.m. PT. According … Continue reading →

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – SRAX Inc. (NASDAQ: SRAX) Scheduled Earnings Conference Call

Posted on June 1, 2022 by MissionIR

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS (“SaaS”) platform, will host an earnings conference call, during which the company will announce and discuss fourth-quarter and full-year earnings … Continue reading →

Posted in SRAX, Inc. SRAX | Leave a comment

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Technology Consistently Enhancing the Oral Administration of Active Pharmaceutical Ingredients

Posted on June 1, 2022 by MissionIR

A global innovator in drug delivery platforms, Lexaria has developed a patented technology, DehydraTECH(TM)  Through research, Lexaria has evidenced that DehydraTECH enhances the efficiency and speed of orally- administered fat-soluble active pharmaceutical ingredients (“APIs”) Lexaria is consistently enhancing the delivery … Continue reading →

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment